KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Profit After Tax: 2009-2025

Historic Profit After Tax for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Sep 2025 value amounting to $1.1 billion.

  • Vertex Pharmaceuticals' Profit After Tax rose 3.59% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 billion, marking a year-over-year increase of 865.96%. This contributed to the annual value of -$535.6 million for FY2024, which is 114.80% down from last year.
  • Vertex Pharmaceuticals' Profit After Tax amounted to $1.1 billion in Q3 2025, which was up 4.84% from $1.0 billion recorded in Q2 2025.
  • Vertex Pharmaceuticals' 5-year Profit After Tax high stood at $1.1 billion for Q1 2024, and its period low was -$3.6 billion during Q2 2024.
  • Over the past 3 years, Vertex Pharmaceuticals' median Profit After Tax value was $968.8 million (recorded in 2023), while the average stood at $531.5 million.
  • In the last 5 years, Vertex Pharmaceuticals' Profit After Tax spiked by 1,109.70% in 2022 and then slumped by 492.44% in 2024.
  • Quarterly analysis of 5 years shows Vertex Pharmaceuticals' Profit After Tax stood at $770.1 million in 2021, then increased by 6.34% to $818.9 million in 2022, then climbed by 18.31% to $968.8 million in 2023, then dropped by 5.76% to $913.0 million in 2024, then grew by 3.59% to $1.1 billion in 2025.
  • Its Profit After Tax stands at $1.1 billion for Q3 2025, versus $1.0 billion for Q2 2025 and $646.3 million for Q1 2025.